• Kristoph Jahnke, Ulrich Keilholz, Diana Lüftner, Eckhard Thiel, and Alexander Schmittel.
• Department of Hematology and Oncology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. kristoph.jahnke@charite.de
• Anticancer Res. 2011 Jan 1; 31 (1): 317-23.

BackgroundA randomized phase II trial was conducted to determine if two non-platinum protocols are able to yield a similar efficacy and toxicity profile as compared to two platinum-based doublets in advanced non-small cell lung cancer (NSCLC).Patients And MethodsA total of 61 patients were randomly assigned to a reference regimen of carboplatin and paclitaxel (repeated every 3 weeks) or to one of three experimental regimens: paclitaxel plus vinorelbine (repeated every 3 or 4 weeks) and carboplatin plus paclitaxel (repeated every 4 weeks).ResultsThe objective remission rate for all the patients was 34.1%. The median progression-free survival for all the patients was 3 months. The median overall survival and one-year overall survival were 6 months and 21.5%, respectively. Toxicity was moderate and manageable. Response, survival and toxicity did not significantly differ between the four treatment groups.ConclusionThe efficacy and toxicity profile of platinum-free combinations is comparable to that of platinum-based doublets.

31 keywords...

hide…